Loading company…
NVasc researches therapies for retinal ischemia.
NVasc is an early-stage ophthalmology company researching therapeutic angiogenesis for retinal ischemia. It is developing leukemia inhibitory factor to stimulate the growth and survival of human choroidal endothelial cells. Founded in 2019, the company is based in California, US. It raised venture funding from Retinal Degeneration Fund in October 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in